

28 April 2025

Dear Colleagues,

Re: Inclisiran prescribing and administration

You may be aware that there has been an increase in the remuneration for providing inclisiran injections from £5 to £15 pound per injection. There are ongoing concerns regarding the safety and resources required for practices to administer inclisiran.

Practices are not contractually obliged to provide this service and the LMC would advise that practices make their own decision about whether to take on the responsibility and costs to prescribe this drug or not. If requested to do so by practices, the LMC will request that the ICB enters into negotiations to develop a LES for inclisiran administration and monitoring.

Please see below for more detailed information.

1. The recent NSHE Funding and supply of inclisiran

31st March 2025 NHS England published new funding for inclisiran prescribing and administration which is live as of 1st April 2025. Details are available below including a practice FAQ.

[NHS England » Funding and supply of inclisiran \(Leqvio®\)](#) For general practice, inclisiran will be reimbursed via ICBs at £60 per injection, against the £45 nominal charge and a £10 increase in funding from £5 to £15 for practice administration activity. NHS England clarified that there are 'no specific incentives' to support the use of inclisiran and the focus 'remains on a clinical pathway.'

2. GPCE news 11th January 2024 reported on Lipid modification resource implications

GPCE, along with RCGP, met several times with NICE about '[Cardiovascular disease: risk assessment and reduction, including lipid modification](#)'. following LMCs concerns about QOF targets and the resource implications of providing alternative lipid lowering agents such as ezetimibe, Inclisiran and PCSK9 inhibitors.

As a result of these meetings, NICE reviewed its [Resource assessment](#), (Dec 2023) which recognises the additional costs and demand on GP appointments associated with prescribing and administration of Inclisiran; and that PCSK9 inhibitor prescribing is mainly hospital based and likely to remain low.

The last position statement from RCGP/BMA (2021) updated in August 2022 states "*Whilst the RCGP and BMA fully support innovation and promoting population health approaches to care, we have ongoing questions regarding the roll-out of this novel medication*" "*The RCGP and BMA will communicate an update to our members once we have further details of the long term trial data in 2026*" [Inclisiran position statement](#)

GPCE LMC news 17th April 2025

GPCE states that they plan to update the existing joint RCGP/BMA guidance for Inclisiran following the NHSE offer and the changes to QOF within the 2025/26 GP contract.

3. NICE guidelines are exactly that and are non-contractual. They should also be viewed in light of GPs' ability to engage patients in shared decision making, so they can make reasoned choices. With no outcome data these conversations may be difficult



4. Practice resources

Practices may consider the number of their patients that are likely to require this treatment and so resources required related to;

- Consultations and communications about any side effects
- Clinician time and appointment to administer.
- Staff training
- Cost of maintaining and administering a long-term recall system

5. GP core contract

The core contract is a national one and cannot be overridden by ICB IMOCs

6. Commissioning gap

GPs are not commissioned to deliver Inclisiran and the administration of inclisiran has been defined as not being a GMS or PMS contractual requirement. Additional resources through LES will need to be in place to undertake this work if GPs feel the increase to the £15 NHSE payment does not adequately reflect the resources required to safely and effectively prescribe and administer this medication.

7. **Enhanced services** are commissioned in other areas to fund this work. A practice may decline to provide this service to their patients on the grounds of the GP core contract does not provide for administration of these medications and the ICB has not commissioned this as a LES

8. Funding and QOF

Acknowledging the £10 increase in funding and the potential impact on QOF points the numbers are likely to be small and practices may like to investigate this as to the impact on their own practice finances.

Your local LMC will welcome your thoughts as to whether they should on your behalf seek a local LES for this service.

Kind regards,

Sara

Dr Sara Riley
Londonwide LMCs Medical Director SEL

Email: sara.riley@lmc.org.uk

Web: www.lmc.org.uk

Twitter: @LondonwideLMCs